跳至主要内容
临床试验/NCT01050634
NCT01050634已完成不适用

Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST) a Non-interventional Trial With Aromasin®

Pfizer0 个研究点目标入组 980 人开始时间: 2005年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Pfizer
入组人数
980
主要终点
Change From Baseline in International Breast Cancer Study Group (IBCSG) Linear Analogues Self-Assessment (LASA) Quality of Life (QoL) Core Questionnaire Scores

研究概览

简要总结

Quality of life under therapy with Aromasin® (exemestane) according to IBCSG (International Breast Cancer Study Group) questionnaire.

Change of the endometrium after switching from tamoxifen to Aromasin® (exemestane).

Deeper knowledge of Adverse Events during routine administration.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

性别
Female
接受健康志愿者

入选标准

  • Early Breast Cancer, post-menopausal, 2-3 yrs adjuvant tamoxifen therapy.

排除标准

  • Not applicable.

研究组 & 干预措施

Observational

干预措施: Aromasin (exemestane) (Drug)

结局指标

主要结局

Change From Baseline in International Breast Cancer Study Group (IBCSG) Linear Analogues Self-Assessment (LASA) Quality of Life (QoL) Core Questionnaire Scores

时间窗: Baseline, Month 12

10 single-item in LASA format(100mm scale): Physical wellbeing (good to lousy); Mood (happy to miserable); Tiredness, Hot flushes, Feeling sick, Use of arm restricted - all none to a lot; Appetite (good to none); Effort to cope with illness (no effort to great deal of effort); Supported by people (much to not at all); Rating life in current condition (perfect to worst health). Individual items scored by measuring distance in mm between left scale anchor and patient's mark, where best QoL=0mm, worst QoL =100mm, and negative changes from baseline=improvement in QoL.Score range=0-100

Change From Baseline in Thickness of Endometrium

时间窗: Baseline, Month 12

Ultrasound measurement. New derived variable for normalization of endometrium thickness: 1 = Endometrium thickness \<=5mm 0 = Endometrium thickness \>5mm

Change From Baseline in IBCSG LASA Items Scores - QoL Module 24-26

时间窗: Baseline, Month 12

Assessment of severity of 13 items (Being irritable, Sweats, Vaginal discharge, dryness, and itching/irritation, Sleep disturbance, Feeling dizzy, Headaches, Bone or joint pain, Troubled by weight gain, Loss of sexual interest, Difficulties in becoming aroused - all from none to severe, and Bothered by treatment related difficulties (not at all to severely). Individual items scored by measuring distance in mm between left scale anchor and patient's mark, where no severity=0mm, maximum severity=100mm and negative changes from baseline=lessening of severity.Score range=0-100

Change From Baseline in 12-Item Short Form Health Survey (SF-12) Summary Subscales (Physical Summary Scale Derived From Items 1-5, 8 and Mental Summary Scale Derived From Items 6, 7, 9-11) Scores

时间窗: Baseline, Month 12

Items: 1.General health 1=poor to 5=excellent 2.Limited moderate activities \& 3.Climbing of stairs 1=lot to 3=not at all 4.Accomplished less \& 5.Limited in kind of work due to physical health, 6.Accomplished less \& 7.Work done less carefully due to emotional problems 1=yes, 2=no 8.Pain interfered with work 1=extremely to 5=not at all 9.Felt calm \& 10.Had lot of energy 1=none to 6=all time 11.Felt downhearted \& 12.Physical health/emotional problems interfered with social activities 1=all time to 6=none of the time. Higher scores=better QoL, positive changes from baseline=improvement in QoL.

Change From Baseline in IBCSG Vaginal Symptoms - QoL Module 24-26

时间窗: Baseline, Month 12

The 3 LASA items concerning vaginal symptoms (discharge, dryness, itching/irritation) were combined as the sum of these 3 items. Lower scores corresponded to better QoL, with negative changes from baseline corresponding to improvements in vaginal symptoms. Total overall score range=0-300, Best score=0, Worst score=300

次要结局

未报告次要终点

研究者

发起方
Pfizer
申办方类型
Industry

相似试验